September 23, 2019 Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration
September 20, 2019 The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T...
September 19, 2019 Innovative Data and Analytics Platform to Accelerate Drug Development for Rare Diseases Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addres
September 18, 2019 C-Path’s Martha A. Brumfield Named Arizona Bioscience Leader of the Year CHANDLER, Ariz., Sept. 18, 2019 — The Arizona Bioindustry Association (AZBio) today announced that Martha A. Brumf
September 13, 2019 Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure
September 3, 2019 The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
August 14, 2019 Conrado et al. 2019 Towards Regulatory Endorsement Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in...
August 12, 2019 C-Path’s Critical Path for Parkinson’s Consortium (CPP) is pleased to welcome Linda L. Restifo, MD, PhD, as a Visiting Scientist C-Path’s Critical Path for Parkinson’s Consortium (CPP) is pleased to welcome Linda L. Restifo, MD, PhD, as a Visiting
August 7, 2019 Funded by FDA, C-Path and NORD to Launch Rare Disease Data and Analytics Platform The collaborative project between the organizations will kick off at a launch meeting in September and will aim to r
